Symphony Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Symphony Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-14,133	Closed	-$798K	–	453
2015 Q3	$798K	Buy	14,133 +1,037	+8%	+$67.2K	0.1%	227
2015 Q2	$774K	Sell	13,096 -8,893	-40%	-$549K	0.1%	212
2015 Q1	$1.37M	Buy	21,989 +12,800	+139%	+$744K	0.16%	136
2014 Q4	$528K	Sell	9,189 -232	-2%	-$12.9K	0.07%	240
2014 Q3	$506K	Sell	9,421 -226	-2%	-$12K	0.05%	252
2014 Q2	$506K	Sell	9,647 -332	-3%	-$17K	0.05%	315
2014 Q1	$527K	Sell	9,979 -6,049	-38%	-$280K	0.05%	300
2013 Q4	$643K	Buy	+16,028	New	+$631K	0.05%	249

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Symphony Asset Management's TEVA Position: Q4 2015 in Review

Symphony Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 14,133 shares — an estimated $798K sold.

Symphony Asset Management first reported a position in TEVA in Q4 2013 and held it in 8 quarters. The position peaked at $1.37M in Q1 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

Symphony Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Symphony Asset Management sold 14,133 Teva Pharmaceuticals shares in Q4 2015, an estimated $798K.
Symphony Asset Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Symphony Asset Management's Teva Pharmaceuticals position peaked at $1.37M in Q1 2015.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on Symphony Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.